https://www.selleckchem.com/products/osmi-1.html
While Alzheimer's dementia (AD) has a prevalence as high as 3-32% and is associated with cognitive dysfunction and the risk of institutionalization, no efficacious and acceptable treatments can modify the course of cognitive decline in AD. Potential benefits of exogenous melatonin on cognition have been divergent across trials. The current network meta-analysis (NMA) was conducted under frequentist model to evaluate the potential benefits of exogenous melatonin supplementation on overall cognitive function in participants with AD in comp
Like
Comment
Share
